Epidemiology of myocardial infarction in France: One year survival in the USIK study;Epidemiologie de l'infarctus du myocarde en France: Survie a 1 an des patients de l'etude USIK

Archives des Maladies du Coeur et des Vaisseaux

Volumn 91, Issue 9, 1998, Pages 1103-1110

  Cambou, J P ^a   Genes N ^b   Vaur, L ^b   Dubroca, I ^c   Etienne, S ^b   Ferrieres J ^a   Danchin, N ^d  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Dir Medicate Labs Roussel Dtamart

^c HMR France   (France)

^d Service de Cardiologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; EPIDEMIOLOGY; FEMALE; FRANCE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PROGNOSIS; SURVIVAL; HEART INFARCTION; MIDDLE AGED; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031717533     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sans S, Kesteloot H, Krombout D. On behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997 ;18 : 1231-48.
2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world : global burden of disease study. Lancet 1997 ; 349 : 1269-76.
3. Cambou JP, Genès N, Vaur L et al. Epidémiologie de l'infarctus du myocarde en France : spécificités régionales. Arch Mal Cœur 1997; 90: 1511-9.
4. Vaur L, Danchin N, Genès N et al. Epidémiologie et prise en charge des infarctus du myocarde àla phase aiguë selon leur degré de dysfonction ventriculaire gauche : résultats de l'étude USIK. Arch Mal Coeur 1997 ; 90 : 1520-8.
5. Colin C, Toselli A, Delahaye F et al. Prise en charge de l'infarctus du myocarde dans la région Rhône-Alpes. Existe-t-il une variation des pratiques ? Arch Mal Coeur 1995 ; 88 : 307-13.
6. Beard T, Carrie D, Pachins B, Jaillais P, Delay M. Bernadet P. Suivi à 1 an de 328 patients atteints d'infarctus au myocarde. Arch Mal Coeur 1994 ; 87 : 869-73.
7. Boissel JP, Peyrieux JC and the EPSIM Research Group. Sub-grouping of post myocardial infarction patients according to their one-year death risk. Eur Heart J 1987 ; 8 : 1272-80.
8. Brandt CM, Wees-Ponchon A, Nisand G et al. Survie dans l'infarctus du myocarde au stade aigu dans un groupe de 369 patients admis consécutivement entre 1988 et 1992. Analyse des facteurs de risque et de la pratique médicale. Arch Mal Coeur 1994 ; 87 : 861-8.
9. Monassier JP, Hanania G, Khalifé K, Frelon JH, Boyreux C, Fournier PY. Stratégies thérapeutiques à la phase aiguë de l'infarctus du myocarde. Résultats du registre STIM 93. Arch Mal Coeur 1996; 89: 281-9.
10. Maheu B, Mansourati J, Guillo P, Larlet JM, Salaun G, Blanc JJ. Mortalité et morbidité à la phase aiguë de l'infarctus du myocarde. Comparaison de trois cohortes de patients hospitalisés espacées de 10 ans. Arch Mal Coeur 1996 ; 89 : 187-92.
11. Groupe de travail «Epidémiologie et Prévention » de la Société française de cardiologie. Fréquence et conditions d'hospitalisation des infarctus récents du myocarde en France. Enquête nationale ENIM 84. Arch Mal Cœur 1987 ; 80 : 1853-64.
12. de Gevigney G, Ecochard R, Colin C et al. Caractéristiques de base et mortalité hospitalière d'une cohorte de 2 515 patients victimes d'infarctus au myocarde : l'étude PRIMA. Arch Mal Coeur 1997 ; 90 : 155.
13. Rustige J, Schiele R, Burczyk U et al. The 60 Minutes Myocardial Infarction Project : Treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J 1997 ; 18 : 1438-46.
14. Rask-Madsen C, Jensen G, Kober L et al. Age-related mortality, clinical heart failure and ventricular fibrillation in 4 259 Danish patients after acute myocardial infarction. Eur Heart J 1997 ; 18 : 1426-31.
15. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994 ; 90 : 583-612.
16. ISIS 3 (Third International Study of Infarct Survival) Collaborative Group : ISIS-3 : a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and or aspirin plus heparin vs aspirin alone among 41 299 cases of suspected myocardial infarction. Lancet 1992 ; 339 : 753-70.
17. Gruppo Italiano per lo studio dello Streptochinasi nell Infarto Miocardico (GISSI) : GISSI-2 : a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990 ; 336 : 65-71.
18. Tavazzi L, Volpi A for the Gissi investigators. Remarks about post infarction prognosis in light of the experience with the Gruppo Italiano per la studio della sopravvivenza nell'infarto miocardico (Gissi) trials. Circulation 1997 ; 95 : 1341-45.
19. Lee KL, Woodlief LH, Topol EJ et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41021 patients. Circulation 1995 ; 91 : 1659-68.
20. Kober L, Torp-Pedersen C, Ottesen M, Rasmussen S, Lessing M, Skagen K. Influence of gender on short- and long-term mortality after acute myocardial infarction. Am J Cardiol 1996 ; 77 : 1052-6.
21. Khattar RS, Basu SK, Raval U, Senior R, Lahiri A. Prognosis value of predischarge exercise testing ejection fraction and ventricular ectopic activity in acute myocardial infarction treated with streptokinase. Am J Cardiol 1996 ; 78 : 136-41.
22. Rouleau JL, Talajic M, Sussex B et al. Myocardial Infarction Patients in the 1990s. Their risk factors, stratification and survival in Canada : the Canadian Assessment of Myocardial Infarction (CAMI) study. J Am Coll Cardiol 1996 ; 27: 1119-27.
23. Kober L, Torp-Pedersen C, Pedersen OD, Hoiberg S, Camm AJ. On behalf or the TRACE study group. Importance or congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 1996 ; 78 : 1124-28.
24. Yusuf S, Anand S, Avezum A, Flather M, Coutinho M. Treatment for acute myocardial infarction. Overview of randomized clinical trials. Eur Heart J 1996 ; 17 (suppl F) : 16-29.
25. Delahaye F, Genoud JL, Colin C et al. Quel traitement anti-ischémique prescrire à la phase aiguë de l'infarctus du myocarde et après. Arch Mal Coeur 1992 ; 85 : 1567-74.
26. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto Miocardico. GISSI-3 : effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994 ; 343 : 1115-22.
27. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4 : a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995 ; 345 : 669-85.
28. Fibrinolytic Therapy Trialists' (FFT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994 ; 343 : 311-22.
29. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996 : 335 : 1253-60.
30. White HD, Norris RM, Brown MA et al. Effects of intravenous streptokinase on left ventricular Function and early survival after acute myocardial infarction. N Engl J Med 1987 : 317 : 850-5.